Drug intelligence / Profile preview

gentamicin + indomethacin

Development stage: Unknown
Lead developer: Bayer HealthCare Pharmaceuticals
Modality: Small Molecules
Administration: Ophthalmic

Overview

A combination drug consisting of gentamicin, an aminoglycoside antibiotic, and indomethacin, a non-steroidal anti-inflammatory drug (NSAID). This combination is primarily used in ophthalmic preparations to treat or prevent inflammation and infection. Gentamicin works by killing bacteria or preventing their growth, while indomethacin exerts anti-inflammatory, analgesic, and antipyretic effects through inhibition of prostaglandin synthesis.

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)30S A-site (Bacterial ribosomal 30S A-site)

Beyond the preview

Go deeper on gentamicin + indomethacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gentamicin + indomethacin.

Explore the full profile